SEARCH

SEARCH BY CITATION

References

  • 1
    Karamitopoulou E. Tumor budding cells, cancer stem cells and epithelial–mesenchymal transition-type cells inpancreatic cancer. Front Oncol 2012; 2: 209.
  • 2
    Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012; 21: 30922.
  • 3
    Kataoka H, Suganuma T, Shimomura T et al. Distribution of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in human tissues. Cellular surface localization of HAI-1 in simple columnar epithelium and its modulated expression in injured and regenerative tissues. J Histochem Cytochem 1999; 47: 67382.
  • 4
    Shimomura T, Denda K, Kitamura A et al. Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor. J Biol Chem 1997; 272: 63706.
  • 5
    Kataoka H, Kawaguchi M. Hepatocyte growth factor activator (HGFA): pathophysiological functions in vivo. FEBS J 2010; 277: 22307.
  • 6
    Kataoka H, Miyata S, Uchinokura S, Itoh H. Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor. Cancer Metast Rev 2003; 22: 22336.
  • 7
    Mukai S, Fukushima T, Naka D, Tanaka H, Osada Y, Kataoka H. Activation of hepatocyte growth factor activator zymogen (pro-HGFA) by human kallikrein 1-related peptidases. FEBS J 2008; 275: 100317.
  • 8
    Toni M, Anatalis TM, Buzza MS, Hodge KM, Hooper JD, Netzel-Arnett S. The cutting edge: membrane-anchored serine protease activities in the pericellular microenvironment. Biochem J 2010; 428: 32546.
  • 9
    Hashimoto T, Kato M, Shimomura T, Kitamura N. TMPRSS13, a type II transmembrane serine protease, is inhibited by hepatocyte growth factor activator inhibitor type 1 and activates pro-hepatocyte growth factor. FEBS J 2010; 277: 4888900.
  • 10
    Cheng H, Fukushima T, Takahashi N, Tanaka H, Kataoka H. Hepatocyte growth factor activator inhibitor type 1 regulates epithelial to mesenchymal transition through membrane-bound serine proteinases. Cancer Res 2009; 69: 182835.
  • 11
    Kato M, Hashimoto T, Shimomura T, Kataoka H, Ohi H, Kitamura N. Hepatocyte growth factor activator inhibitor type 1 inhibits protease activity and proteolytic activation of human airway trypsin-like protease. J Biochem 2012; 151: 17987.
  • 12
    Owen KA, Qiu D, Alves J et al. Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA. Biochem J 2010; 426: 21928.
  • 13
    Bhatt AS, Welm A, Farady CJ, Vásquez M, Wilson K, Craik CS. Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway. Proc Natl Acad Sci USA 2007; 104: 57716.
  • 14
    Ustach CV, Huang W, Conley-LaComb MK et al. A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancer. Cancer Res 2010; 70: 963140.
  • 15
    Hurst NJ, Najy AJ, Ustach CV, Movilla L, Kim HR. Platelet-derived growth factor-C (PDGF-C) activation by serine proteases: implications for breast cancer progression. Biochem J 2012; 441: 90918.
  • 16
    Bocheva G, Rattenholl A, Kempkes C et al. Role of matriptase and proteinase-activated receptor-2 in nonmelanoma skin cancer. J Invest Dermatol 2009; 129: 181623.
  • 17
    Camerer E, Barker A, Duong DN et al. Local protease signaling contributes to neural tube closure in the mouse embryo. Dev Cell 2010; 18: 2538.
  • 18
    Hoshiko S, Kawaguchi M, Fukushima T et al. Hepatocyte growth factor activator inhibitor type 1 is a suppressor of intestinal tumorigenesis. Cancer Res 2013; 73: 265970.
  • 19
    Domoto T, Takino T, Guo L, Sato H. Cleavage of hepatocyte growth factor activator inhibitor-1 by membrane-type MMP-1 activates matriptase. Cancer Sci 2012; 103: 44854.
  • 20
    Nagaike K, Kohama K, Uchiyama S et al. Paradoxically enhanced immunoreactivity of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in cancer cells at the invasion front. Cancer Sci 2004; 95: 72835.
  • 21
    Kataoka H, Uchino H, Denda K et al. Evaluation of hepatocyte growth factor activator inhibitor expression in normal and malignant colonic mucosa. Cancer Lett 1998; 128: 21927.
  • 22
    Zeng L, Cao J, Zhang X. Expression of serine protease SNC19/matriptase and its inhibitor hepatocyte growth factor activator inhibitor type 1 in normal and malignant tissues of gastrointestinal tract. World J Gastroenterol 2005; 11: 62027.
  • 23
    Vogel LK, Saebo M, Skjelbred CF et al. The ratio of matriptase/HAI-1 mRNA is higher in colorectal cancer adenomas and carcinomas than corresponding tissue from control individuals. BMC Cancer 2006; 6: 176.
  • 24
    Kataoka H, Hamasuna R, Itoh H, Kitamura N, Koono M. Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma. Cancer Res 2000; 60: 614859.
  • 25
    Baba T, Kawaguchi M, Fukushima T et al. Loss of membrane-bound serine protease inhibitor HAI-1 induces oral squamous cell carcinoma cells' invasiveness. J Pathol 2012; 228: 18192.
  • 26
    Kitamura N, Iwamura T, Taniguchi S et al. High collagenolytic activity in spontaneously highly metastatic variants derived from a human pancreatic cancer cell line (SUIT-2) in nude mice. Clin Exp Metastasis 2000; 18: 56171.
  • 27
    Fukushima T, Kawaguchi M, Yamasaki M, Tanaka H, Yorita K, Kataoka H. Hepatocyte growth factor activator inhibitor type 1 suppresses metastatic pulmonary colonization of pancreatic carcinoma cells. Cancer Sci 2011; 102: 40713.
  • 28
    Hoffman RM. Orthotopic is orthodox: why are orthotopic-transplant metastatic models different from all other models? J Cell Biochem 1994; 56: 13.
  • 29
    Loukopoulos P, Kanetaka K, Takamura M, Shibata T, Sakamoto M, Hirohashi S. Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. Pancreas 2004; 29: 193203.
  • 30
    Kohama K, Kawaguchi M, Fukushima T, Lin CY, Kataoka H. Regulation of pericellular proteolysis by hepatocyte growth factor activator inhibitor type 1 (HAI-1) in trophoblast cells. Hum Cell 2012; 25: 10010.
  • 31
    Ikeda O, Egami H, Ishiko T et al. Expression of proteinase-activated receptor-2 in human pancreatic cancer: a possible relation to cancer invasion and induction of fibrosis. Int J Oncol 2003; 22: 295300.
  • 32
    Yada K, Shibata K, Matsumoto T, Ohta M, Yokoyama S, Kitano S. Protease-activated receptor-2 regulates cell proliferation and enhances cyclooxygenase-2 mRNA expression in human pancreatic cancer cells. J Surg Oncol 2005; 89: 7985.
  • 33
    Fidler IJ. Critical factors in the biology of human cancer metastases: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res 1990; 50: 61308.
  • 34
    Elste AP, Petersen I. Expression of proteinase-activated receptor 1–4 (PAR 1–4) in human cancer. J Mol Histol 2010; 41: 8999.
  • 35
    Sanders AJ, Parr C, Mason MD, Jiang WG. Suppression of hepatocyte growth factor activator inhibitor-1 leads to a more aggressive phenotype of prostate cancer cells in vitro. Int J Mol Med 2007; 20: 6139.
  • 36
    Nakamura K, Hongo A, Kodama J, Hiramatsu Y. The role of hepatocyte growth factor activator inhibitor (HAI)-1 and HAI-2 in endometrial cancer. Int J Cancer 2011; 128: 261324.
  • 37
    Komaki W, Fukushima T, Tanaka H, Itoh H, Chosa E, Kataoka H. Expression of hepatocyte growth factor activator inhibitor type 1 on the epithelial cell surface is regulated by hypoxic and oxidative stresses. Virchow Arch 2008; 453: 34757.
  • 38
    Nakamura K, Abarzua F, Kodama J et al. Expression of hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) in ovarian cancer. Int J Oncol 2009; 34: 34553.
  • 39
    Nakamura K, Abarzua F, Hongo A et al. The role of hepatocyte growth factor activator inhibitor-1 (HAI-1) as a prognostic indicator in cervical cancer. Int J Oncol 2009; 35: 23948.
  • 40
    Saleem M, Adhami VM, Zhong W et al. A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev 2006; 15: 21727.
  • 41
    Kauppinen JM, Kosma VM, Soini Y et al. ST14 gene variant and decreased matriptase protein expression predict poor breast cancer survival. Cancer Epidemiol Biomarkers Prev 2010; 19: 213342.
  • 42
    Funagayama M, Kondo K, Chijiiwa K, Kataoka H. Expression of hepatocyte growth factor activator inhibitor type 1 in human hepatocellular carcinoma and postoperative outcomes. World J Surg 2010; 34: 156371.